Biogen plans to launch a virtual study with Apple this year to identify early signs of mild cognitive impairment. The study is expected to launch in the second half of 2021.
MedCity News
One year after founding, startup EQRx raises $500M to advance goal of cheaper cancer drugs
The latest funding brings total investment in the company to $750 million. The money has gone, in part, toward licensing of promising drug candidates in breast, lung and other cancers.
Shares1
A high-powered startup has raised $500 million toward its goal of making drugs for cancer and other chronic diseases more affordable and unveiled some of its most promising candidates.
The company, Cambridge, Massachusetts-based EQRx, was co-founded last January by a prominent health policy expert and a biotech executive, among others. Its latest funding, announced this week, brings its total haul to roughly $750 million.
Roughly a third of adults had a telehealth visit in the first 6 months of the pandemic, according to a new survey conducted by the Urban Institute. But not everyone who wanted a telehealth visit was able to access it, leaving some adults with unmet care needs.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
MedCity News
Medtronic CEO expects to submit renal denervation data to FDA this year, overcoming previous failures
Medtronic suffered a shocking setback back in 2014 when its Symplicity 3 pivotal trial failed to meet its primary endpoint of reducing blood pressure meaningfully. Now it is gearing up to present new data to the FDA.
Shares1
If Medtronic is successful in bringing its renal denervation product to the U.S. market to treat drug-resistant hypertension as its current CEO Geoff Martha expects to, the entire saga could be summarized with Chumbawamba’s famous song from the late 1990s:
I get knocked down, but I get up again